Literature DB >> 17621876

Current status of tissue kallikrein inhibitors: importance in cancer.

Kanti D Bhoola1, Neil L Misso, Anupam Naran, Philip J Thompson.   

Abstract

The past decade has seen an increase in the understanding of the structure and function of protease inhibitors. The molecular basis of the interaction between a variety of biological substrates or synthetic inhibitors and serine proteases of the kallikrein family has provided insights into inhibitor protein-protease reactive site interactions, which have proved of value in the design of new kallikrein inhibitors. This review focuses on the current understanding of the functional status of kallikrein inhibitors, which include a variety of molecules derived from plant, reptile and mammalian sources, as well as synthetic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621876

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

1.  Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway.

Authors:  V Sgnaolin; T C B Pereira; M R Bogo; R Zanin; A M O Battastini; F B Morrone; M M Campos
Journal:  Invest New Drugs       Date:  2012-12-07       Impact factor: 3.850

Review 2.  Extracellular proteases as targets for drug development.

Authors:  Mare Cudic; Gregg B Fields
Journal:  Curr Protein Pept Sci       Date:  2009-08       Impact factor: 3.272

3.  Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation.

Authors:  Ingrid Lopatko Fagerström; Anne-Lie Ståhl; Maria Mossberg; Ramesh Tati; Ann-Charlotte Kristoffersson; Robin Kahn; Jean-Loup Bascands; Julie Klein; Joost P Schanstra; Mårten Segelmark; Diana Karpman
Journal:  EBioMedicine       Date:  2019-08-20       Impact factor: 8.143

4.  A Computational Framework to Identify Transcriptional and Network Differences between Hepatocellular Carcinoma and Normal Liver Tissue and Their Applications in Repositioning Drugs.

Authors:  Aimin Hu; Zheng Wei; Zuxiang Zheng; Bichao Luo; Jieming Yi; Xinhong Zhou; Changjiang Zeng
Journal:  Biomed Res Int       Date:  2021-09-23       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.